Samsung生物logics报告,2024年收入猛增23%,达到4.55万亿韩元,并计划扩大。 Samsung Biologics reports a 23% revenue jump to KRW 4.55 trillion for 2024, with plans to expand.

Samsung生物logics报告,2024年,4.55万亿韩元的收入增加了23%,营业利润上升19%,达到1.32万亿韩元。 Samsung Biologics reported a 23% increase in revenue to KRW 4.55 trillion for 2024, with an operating profit up 19% to KRW 1.32 trillion. 该公司为110多个客户提供服务,包括17家顶级药剂公司,超过43亿美元的合同价值。 Serving over 110 clients, including 17 top pharma firms, the company surpassed a USD 4.3 billion contract value. 预计未来的增长将在第4号工厂全面运营和第5号工厂于2025年4月启动,将产能扩大到784,000升. Future growth is expected with full Plant 4 operations and the April 2025 launch of Plant 5, expanding capacity to 784,000 liters. Samsung生物logics也在投资于人工智能、数字转型和可持续性。 Samsung Biologics is also investing in AI, digital transformation, and sustainability.